In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Decentralising research
A thought leadership piece which explores how pharma and biotech companies are shifting from traditional trial models to agile, patient-centric processes driven by digital technologies to improve R&D productivity.
-
The quest for increased efficiency in personalised medicine clinical trials
A thought leadership piece by Lawrence Johnson and Cynthia Spittle discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions (pages 16-17).
-
Patient centricity: Exploring the patient perspective from different angles
An article exploring the challenges and potential solutions of integrating patient insight for improved outcomes from the perspective of a patient advocate, clinical investigator and pharmaceutical executive.
-
BARDA reselects ICON as preferred partner
An article focused on the BARDA announcement that ICON continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development.
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
ICON’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
-
Listening to the patient for better outcomes
ICON’s Gretchen Goller discusses the importance of establishing and maintaining patient connection, and overcoming structural barriers with decentralised and hybrid trials. Read more in this PharmaVOICE article.
-
What clinical holds and pauses mean for COVID-19 countermeasure timelines
ICON’s Nuala Murphy and David Morse discuss trial pauses and clinical halts after three high-profile COVID-19 trials are temporarily halted as a result of potential safety issues being flagged by independent Data and Safety Monitoring Boards. Read more in this Biocentury article.
-
Pandemic priorities
The requirements for global HTA/reimbursement consideration have changed and are continuing to evolve in response to the current pandemic. This PharmaTimes article considers how drug sponsors can navigate a path to reimbursement success and market access for drugs that were in development prior to the pandemic.
-
Navigating cell therapy manufacturing amid pandemic woes
An article featuring expert commentary from ICON's Tamie Joeckel on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
-
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
This published study conducted by ICON's Health Economics team and Bristol-Myers Squibb evaluates a cost-effective new treatment for melanoma patients in Japan.
